IL285493A - Crystalline forms of rsk inhibitor - Google Patents

Crystalline forms of rsk inhibitor

Info

Publication number
IL285493A
IL285493A IL285493A IL28549321A IL285493A IL 285493 A IL285493 A IL 285493A IL 285493 A IL285493 A IL 285493A IL 28549321 A IL28549321 A IL 28549321A IL 285493 A IL285493 A IL 285493A
Authority
IL
Israel
Prior art keywords
crystalline forms
rsk inhibitor
rsk
inhibitor
crystalline
Prior art date
Application number
IL285493A
Other languages
English (en)
Hebrew (he)
Original Assignee
Phoenix Molecular Designs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Molecular Designs filed Critical Phoenix Molecular Designs
Publication of IL285493A publication Critical patent/IL285493A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL285493A 2019-02-11 2021-08-10 Crystalline forms of rsk inhibitor IL285493A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962804076P 2019-02-11 2019-02-11
PCT/IB2020/000092 WO2020165646A1 (en) 2019-02-11 2020-02-10 Crystalline forms of an rsk inhibitor

Publications (1)

Publication Number Publication Date
IL285493A true IL285493A (en) 2021-09-30

Family

ID=72043971

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285493A IL285493A (en) 2019-02-11 2021-08-10 Crystalline forms of rsk inhibitor

Country Status (9)

Country Link
US (1) US12378245B2 (cg-RX-API-DMAC7.html)
EP (1) EP3924352A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022520382A (cg-RX-API-DMAC7.html)
KR (1) KR20210126077A (cg-RX-API-DMAC7.html)
CN (1) CN113677681A (cg-RX-API-DMAC7.html)
AU (1) AU2020222056A1 (cg-RX-API-DMAC7.html)
CA (1) CA3129722A1 (cg-RX-API-DMAC7.html)
IL (1) IL285493A (cg-RX-API-DMAC7.html)
WO (1) WO2020165646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
US20260193283A1 (en) * 2022-06-07 2026-07-09 Kinoteck Therapeutics Co., Ltd. Carboxamide derivative having rsk inhibitory effect, pharmaceutical composition comprising same, and use thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP2001501946A (ja) 1996-10-08 2001-02-13 イーライ・リリー・アンド・カンパニー 新規セロトニン5―ht▲下1f▼アゴニスト
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
AU741482B2 (en) 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
EP1495016A2 (en) 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
AU2006279992A1 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2690410C (en) 2007-06-12 2015-09-29 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
NZ583689A (en) 2007-09-14 2012-04-27 Univ Michigan F1f0-atpase inhibitors and related methods
GB0718870D0 (en) 2007-09-27 2007-11-07 Univ Dundee Modulation of RSK
KR20120055608A (ko) * 2009-08-06 2012-05-31 메르크 파텐트 게엠베하 신규한 이환 우레아 화합물
WO2011071725A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
US9150577B2 (en) 2009-12-07 2015-10-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
MX343327B (es) 2011-02-17 2016-11-01 Nestec Sa Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
WO2013181742A1 (en) 2012-06-04 2013-12-12 Phoenix Molecular Diagnostics Ltd. Methods of inhibiting rsk for treatment of breast cancer
CN103724251B (zh) 2014-01-18 2015-07-22 福州大学 一种靶向stat3的小分子化合物及其制备方法和应用
CA2944610C (en) 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
ES2959536T3 (es) * 2015-12-14 2024-02-26 Senhwa Biosciences Inc Formas cristalinas de análogos de quinolona y sus sales
WO2017141116A1 (en) * 2016-02-19 2017-08-24 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor

Also Published As

Publication number Publication date
EP3924352A1 (en) 2021-12-22
JP2022520382A (ja) 2022-03-30
AU2020222056A1 (en) 2021-10-07
WO2020165646A1 (en) 2020-08-20
US20220112193A1 (en) 2022-04-14
CN113677681A (zh) 2021-11-19
CA3129722A1 (en) 2020-08-20
KR20210126077A (ko) 2021-10-19
EP3924352A4 (en) 2022-11-16
US12378245B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
IL282552A (en) Crystalline forms of MNK inhibitors
IL278413A (en) Salts of FGFR inhibitor
IL313281B1 (en) Mta-cooperative prmt5 inhibitors
EP3924352A4 (en) CRYSTALLINE FORMS OF AN RSK INHIBITOR
EP3982949A4 (en) Inhibitors of sarm1
IL289879A (en) Solid forms of hpk1 inhibitor
EP4028013A4 (en) INHIBITORS OF SARM1
GB201914860D0 (en) Inhibitor compounds
IL289929A (en) Crystal forms of cd73 inhibitor
IL267393A (en) Crystal forms of a Janus kinase inhibitor
IL290087A (en) inhibitory substances
SG11202100267TA (en) Solid forms of an azolopyrimidine compound
IL276853A (en) Aggregate forms of SGC stimulator
IL277806A (en) Growth inhibitor
IL289214A (en) Crystalline forms of plasma kallikrein inhibitors
GB201905328D0 (en) Inhibitor compounds
IL285427A (en) Crystal forms of jak2 inhibitor
GB201507036D0 (en) Crystalline enzyme inhibitor compound
IL292847A (en) Crystalline forms of magl inhibitor
GB201912411D0 (en) Crystalline forms of ivosidenib
IL291368A (en) Inhibits expression of methadherin
HK40064714A (en) Crystalline forms of an rsk inhibitor
GB201915908D0 (en) Crystalline forms of entrectinib
SG11202106561RA (en) Crystalline forms of a par4 inhibitor
GB201708999D0 (en) Recrystallization Inhibitor